Premium
GR Ligands: Can We Improve the Established Drugs?
Author(s) -
Rehwinkel Hartmut,
Schäcke Heike
Publication year - 2006
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.200600070
Subject(s) - drug , pharmacology , drug discovery , medicine , drug development , computational biology , chemistry , bioinformatics , biology
Glucocorticoids (GCs) represent the most effective therapy for acute and chronic inflammatory disorders, yet they can elicit severe side effects. New classes of GC receptor ligands appear to have all of the benefits and fewer side effects and have prompted new research into an old drug target. Compound A (shown) is the latest addition to this exciting development.